SOST and osteoporosis: Our results demonstrate for the first time that blocking sclerostin with a neutralizing antibody, currently under advanced investigation for the treatment of osteoporosis, induces a thermogenic gene program in human BM-MSCs, and increases the expression of UCP1, a driver of mitochondrial heat generation and energy expenditure.